HomeProductsBioactive CompoundsNeuronal SignalingAdrenergic ReceptorTerazosin
Chemical structure of CAS 63590-64-7

Terazosin

In Stock•Starting at $116 for 100 mg
CAS No.63590-64-7
MDL No.MFCD00467965
MFC19H25N5O4
MW387.40
InChI KeyVCKUSRYTPJJLNI-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
100 mgTo Be Confirmed$116In Stock
500 mgTo Be Confirmed$363In Stock
1 gTo Be Confirmed$636In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Terazosin is a quinazoline, piperazine, furan, and primary amino compound. It functions as an antineoplastic, antihypertensive, and alpha-adrenergic antagonist.

CAS No.63590-64-7
Product NameTerazosin

Biological Targets

ADRA1A·ADRA1D·ADRA1B

Associated Conditions

atherosclerosis·benign prostatic hyperplasia·Lewy body dementia·Parkinson disease·type 2 diabetes mellitus·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

The Journal of urology • Vol. 165, Issue 1 • 2001
PMID: 11125359DOI: 10.1097/00005392-200101000-00010

Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.

Urology • Vol. 57, Issue 1 • 2001
PMID: 11164146DOI: 10.1016/s0090-4295(00)00854-2

Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.

The Prostate • Vol. 46, Issue 1 • 2001
PMID: 11170131DOI: 10.1002/1097-0045(200101)46:1<45::aid-pros1007>3.0.co;2-u

Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.

Nature medicine • Vol. 7, Issue 2 • 2001
PMID: 11175818DOI: 10.1038/84529

Documentation

Similar Products